Portal de Periódicos da CAPES

Revisão Produção Nacional Revisado por pares

BIBTEX RIS

Recognition of the phenotype of thalidomide embryopathy in countries endemic for leprosy

2013; Lippincott Williams & Wilkins; Volume: 22; Issue: 2 Linguagem: Inglês

10.1097/mcd.0b013e32835ffc58

1473-5717

Fernanda Sales Luiz Vianna, Lavínia Schüler‐Faccini, Júlio César Loguercio Leite, Silvia Helena C. de Sousa, Léa Márcia Melo da Costa, Murilo F. Dias, Elaine Faria Morelo, Maria Juliana R. Doriqui, Claudia M. Maximino, Maria Teresa Vieira Sanseverino,

Chronic Lymphocytic Leukemia Research

Thalidomide is the best-known teratogen worldwide. It was first marketed as a sedative in the late 1950s, but the birth of ~10 000 children with birth defects resulted in the withdrawal of thalidomide from the market in 1962. Thalidomide embryopathy affects almost all organs but the main defects are concentrated in the limbs, eyes, ears, and heart. Shortly after the withdrawal of thalidomide from the market, its effectiveness in the treatment of erythema nodosum leprosum, an inflammatory condition resulting from leprosy, was reported and since the mid-1990s, the drug has been used widely in the treatment of cancers and autoimmune diseases, among other conditions. 40 000 new cases of leprosy are diagnosed every year in Brazil. Although there is a strict legislation for the prescription and use of thalidomide in Brazil, cases of thalidomide embryopathy have continued to be reported. Here, we present two new cases of thalidomide embryopathy identified in 2011 and review the major clinical findings in the literature that can aid the identification of the embryopathy.